Therapeutic drug monitoring for tomorrow

European Journal of Clinical Pharmacology

Volumn 69, Issue SUPPL. 1, 2013, Pages

  Eliasson, Erik ^a,b   Lindh, Jonatan D ^a,b   Malmström, Rickard E ^a,b   Beck, Olof ^a,b   Dahl, Marja Liisa ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Analytical chemistry; Antibiotics; Anticoagulants; Dose regimen; Pharmacogenetics; Pharmacokinetics; Psychotropic drugs

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; WARFARIN; DRUG;

CRITICALLY ILL PATIENT; DRUG ANALYSIS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MENTAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REVIEW; CHEMICAL ANALYSIS; MEDICAL RESEARCH;

BIOMEDICAL RESEARCH; CHEMISTRY TECHNIQUES, ANALYTICAL; DRUG MONITORING; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84886734099     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1504-x     Document Type: Review

References (48)

1. Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, Rawlins M, Reidenberg M, Sjöqvist F, Smith T, Thuerman P, Walubo A, Orme M, Sjöqvist F (2010) Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 107:531-559
2. Asberg M, Cronholm B, Sjöqvist F, Tuck D (1971) Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 3:331-334
3. Noone P, Parsons TM, Pattison JR, Slack RC, Garfield-Davies D, Hughes K (1974) Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis. Br Med J 1:477-481
4. Duhme DW, Greenblatt DJ, Koch-Weser J (1974) Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med 80:516-519
5. Levy G, Ellis EF, Koysooko R (1974) Indirect plasma-theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva. Pediatrics 53:873-876
6. Eichelbaum M, Bertilsson L, Lund L, Palmér L, Sjöqvist F (1976) Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy. Eur J Clin Pharmacol 9:417-421
7. Sjöqvist F, Eliasson E (2007) The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 81:899-902
8. Dahl M-L, Sjöqvist F (2000) Pharmacogenetic methods as a comment to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 22:114-116
9. Saint-Marcoux F, Sauvage FL, Marquet P (2007) Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 388:1327-1340
10. Sallustio BC (2010) LC-MS/MS for immunosuppressant therapeutic drug monitoring. Bioanalysis 2:1141-1153
11. Meyer MR, Maurer HH (2012) Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem 403:1221-1231
12. Mittelstrass K, Ried JS, Yu Z, Krumsiek J, Gieger C, Prehn C, Roemisch-Margl W, Polonikov A, Peters A, Theis FJ, Meitinger F, Krononberg F, Weidinger S, Wichmann HE, Suhre K, Wang-Sattler R, Adamski J, Illig T (2011) Discovery of sexual dimorphism in metabolic and genetic biomarkers. PLoS Genet 7:1-11
13. Broecker S, Herre S, Wüst B, Zweigenbaum J, Pragst F (2011) Development and practical application of a library of CID accurate mass spectra of more than 2,500 toxic compounds for systematic toxicological analysis by LC-QTOF-MS with data-dependent acquisition. Anal Bioanal Chem 400:101-117
14. Heine R, Beijnen JH, Huitema AD (2009) Bioanalytical issues in patient friendly sampling methods for therapeutic drug monitoring: focus on antiretroviral drugs. Bioanalysis 1:1329-1338
15. Gallardo E, Barroso M, Queiroz JA (2009) Current technologies and considerations for drug bioanalysis in oral fluid. Bioanalysis 1:637-667
16. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA (2012) Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2:35
17. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators (2012) Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 40:1523-1528
18. Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J (2012) What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 39:455-457
19. González de Molina FJ, Ferrer R (2011) Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care 15:175
20. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F (2010) Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126
21. Hanberger H, Edlund C, Furebring M, G Giske C, Melhus A, Nilsson LE, Petersson J, Sjölin J, Ternhag A, Werner M, Eliasson E; Swedish Reference Group for Antibiotics (SRGA) (2012) Rational use of aminoglycosides - Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis 45(3):161-75
22. Pasqualotto AC, Howard SJ, Moore CB, Denning DW (2007) Flucytosine therapeutic monitoring: 15 years' experience from the UK. J Antimicrob Chemother 59:791-793
23. Rybak M, Lomaestro B, Rotschafer JC et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98
24. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG (2010) Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 123:182.e1-182.e7
25. Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330-1336
26. Van Herendael B, Jeurissen A, Tulkens PM, Vlieghe E, Verbrugghe W, Jorens PG, Ieven M (2012) Continuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin? Ann Intensive Care 2:22
27. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332-339
28. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30-39
29. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10
30. Dahl M-L, Bertilsson L (1993) Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3:61-70
31. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carebamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368-374
32. Bertilsson L, Carrillo JA, Dahl M-L, LLerena A, Alm C, Bondesson U, Lindström L, Rodriquez de la Rubia I, Ramos S, Benitez J (1994) Clozapine disposition covaries with the CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473
33. Bengtsson F (2004) Therapeutic drug monitoring of psychotropic drugs, TDM "nouveau". Ther Drug Monit 26:145-151
34. Brünen S, Vincent PD, Baumann P, Hiemke C, Havemann-Reinecke U (2011) Therapeutic drug monitoring for drugs used in the treatment fo substance-related disorders: Literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit 33:561-572
35. Carlquist JF, Anderson JL (2011) Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 124:2554-2559
36. Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol 65:365-375
37. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784-792
38. Lazo-Langner A, Kovacs MJ (2010) Predicting warfarin dose. Curr Opin Pulm Med 16:426-431
39. Malmström RE (2009) New anticoagulants: focus on currently approved oral factor Xa and factor IIa inhibitors. In: Antovic JP, Blombäck M (eds) Essential guide to blood coagulation. Wiley-Blackwell, Oxford, pp 91-102
40. Conolly SJ, for the RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
41. Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883-891
42. Granger CB et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981-992
43. Federal Drug Administration (2010) Questions dabigatran. Available at: www.fda.gov
44. European Medicines Agency (EMA). Summary of product characteristics. Pradaxa (dabigatran). Available at: www.ema.europa.eu
45. European Medicines Agency (EMA). Summary of product characteristics. Xarelto (rivaroxaban). Available at: www.ema.europa.eu
46. European Medicines Agency (EMA).Summary of product characteristics. Eliquis (apixaban). Available at: www.ema.europa.eu
47. Samama MM, Guinet C, Le Flem L, Ninin E, Debue JM (2013) Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 35:140-146
48. Antovic JP, Skeppholm M, Eintrei J, Eriksson-Boija E, Söderblom L, Rönquist Y, Pohanka A, Beck O, Norberg E-M, Hjemdahl P, Malmström RE (2013). How to monitor dabigatran when needed: comparison of coagulation laboratory methods and dabigatran concentrations in plasma. Abstract. 24th ISTH Congress and 59th Annual Scientific and Standardization Committee (SSC) Meeting, Amsterdam